secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001651308-25-000074
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene reports Q1 2025 revenue $1.1B (+49% YoY); first GAAP profitable quarter with net income $1.3M
--------------------------------------------------------------------------------

- Total revenue $1.1B (+49% YoY); BRUKINSA sales $792M (+62%), now overall BTKi leader.
- First GAAP profitable quarter: net income $1.3M vs loss $251M in Q1 2024; adjusted net income $136M.
- Adjusted diluted EPS $1.22 vs ($1.40) prior year; operating cash flow significantly improved.
- Shareholder approved renaming to BeOne Medicines and redomicile to Switzerland; investor R&D Day June 26.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130825000074/0001651308-25-000074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130825000074/bgne-20250507.htm
  HTML page:      https://secwatch.observer/filing/0001651308-25-000074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer